North Carolina-based FHI has been selected as one of six preferred providers offering their clinical research expertise to a consortium of 14 global health product development partnerships (PDPs). The consortium of PDPs is working to develop and deliver affordable treatments and to improve the lives of vulnerable people across the globe.
FHI’s 40 years of research experience has focused on infectious and neglected diseases, such as HIV, HSV, HPV, other sexually transmitted diseases, malaria, and seasonal and pandemic influenza.
“This consortium has the potential to find cures for the most widespread diseases, like tuberculosis, malaria, influenza, dengue fever, HIV and Chagas disease,” said Albert J. Siemens, FHI chairman and chief executive officer. “FHI is honored to be selected as a preferred provider, offering our expertise and experience to the critical work being undertaken by the PDPs.”
FHI partners with government, non-governmental, and private sector entities on major pharmaceutical and biotechnology clinical trials worldwide.